FABP1 and metabolic dysfunction-associated steatotic liver disease: To identify the discriminatory significance of LFABP levels in patients with NAFLD, NASH, and non-NASH vs. controls, as well as in NASH patients vs. non-NASH patients, ROC curves were generated (Figure 3).